Psychopharmacology

, Volume 232, Issue 16, pp 3091–3100 | Cite as

New onset executive function difficulties at menopause: a possible role for lisdexamfetamine

  • C. Neill Epperson
  • Sheila Shanmugan
  • Deborah R. Kim
  • Sarah Mathews
  • Kathryn A. Czarkowski
  • Jeanette Bradley
  • Dina H. Appleby
  • Claudia Iannelli
  • Mary D. Sammel
  • Thomas E. Brown
Original Investigation

Abstract

Rationale

Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women.

Objective

This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints.

Methods

Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40–60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest.

Results

Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range.

Conclusions

LDX 40–60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.

Keywords

Menopause Cognition Executive function ADHD Psychostimulant Lisdexamfetamine Brown Attention Deficit Disorder Scale Verbal memory Paragraph recall 

Supplementary material

213_2015_3953_MOESM1_ESM.pdf (368 kb)
ESM 1(PDF 368 kb)

References

  1. Arnsten AF (2009) The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 154:I-S43PubMedCentralPubMedCrossRefGoogle Scholar
  2. Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H (2014) Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 28:837–846PubMedCentralPubMedCrossRefGoogle Scholar
  3. Barkley RA, Murphy KR (2010) Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol 25:157–173PubMedCentralPubMedCrossRefGoogle Scholar
  4. Barrouillet P, Bernardin S, Portrat S, Vergauwe E, Camos V (2007) Time and cognitive load in working memory. J Exp Psychol Learn Mem Cogn 33:570–585PubMedCrossRefGoogle Scholar
  5. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedCrossRefGoogle Scholar
  6. Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897PubMedCrossRefGoogle Scholar
  7. Beglinger LJ, Adams WH, Paulson H, Fiedorowicz JG, Langbehn DR, Duff K, Leserman A, Paulsen JS (2009) Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 29:484–487PubMedCentralPubMedCrossRefGoogle Scholar
  8. Brown TE (2014) Smart but stuck: emotions in teens and adults with ADHD. Jossey-Bass, San FranciscoGoogle Scholar
  9. Brown TE, Landgraf JM (2010) Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med 122:42–51PubMedCrossRefGoogle Scholar
  10. Brown RT, Perrin JM (2007) Measuring outcomes in attention-deficit/hyperactivity disorder. J Pediatr Psychol 32:627–630PubMedCrossRefGoogle Scholar
  11. Brown TE, Reichel PC, Quinlan DM (2009) Executive function impairments in high IQ adults with ADHD. J Atten Disord 13:161–167PubMedCrossRefGoogle Scholar
  12. Brown TE, Brams M, Gao J, Gasior M, Childress A (2010) Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med 122:7–17PubMedCrossRefGoogle Scholar
  13. Brown TE, Brams M, Gasior M, Adeyi B, Babcock T, Dirks B, Scheckner B, Wigal T (2011) Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin 27(Suppl 2):23–33PubMedCrossRefGoogle Scholar
  14. Brunner E, Domhof S, Langer F (2002) Nonparametric analysis of longitudinal data in factorial experiments. Wiley, New YorkGoogle Scholar
  15. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213PubMedCrossRefGoogle Scholar
  16. Dolder CR, Davis LN, McKinsey J (2010) Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Ann Pharmacother 44(10):1624–32PubMedCrossRefGoogle Scholar
  17. Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE (2011) Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. Menopause 18:542–548PubMedCentralPubMedCrossRefGoogle Scholar
  18. Epperson CN, Sammel MD, Freeman EW (2013) Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab 98:3829–3838PubMedCentralPubMedCrossRefGoogle Scholar
  19. First MB, Spitzer RL, Gibbon M, Williams JB (1995) Structured clinical interview for DSM-IV Axis I disorders—patient edition SCID-I/PGoogle Scholar
  20. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS (2012) A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 107:165–174PubMedCrossRefGoogle Scholar
  21. Greendale GA, Derby CA, Maki PM (2011) Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Obstet Gynecol Clin North Am 38(3):519–35PubMedCentralPubMedCrossRefGoogle Scholar
  22. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedCrossRefGoogle Scholar
  23. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296PubMedCrossRefGoogle Scholar
  24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381PubMedCentralPubMedCrossRefGoogle Scholar
  25. Jacobs E, D’Esposito M (2011) Estrogen shapes dopamine-dependent cognitive processes: implications for women’s health. J Neurosci 31:5286–5293PubMedCentralPubMedCrossRefGoogle Scholar
  26. Johnson RL, Block I, Gold MA, Markwell S, Zupancic M (2010) Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology 19:955–958PubMedCrossRefGoogle Scholar
  27. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B (1999) Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol 12:168–179PubMedCrossRefGoogle Scholar
  28. Kurtz MM, Ragland JD, Bilker W, Gur RC, Gur RE (2001) Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia. Schizophr Res 48:307–316PubMedCrossRefGoogle Scholar
  29. Luetters C, Huang MH, Seeman T, Buckwalter G, Meyer PM, Avis NE, Sternfeld B, Johnston JM, Greendale GA (2007) Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the Study of Women’s Health Across the Nation (SWAN). J Womens Health (Larchmt) 16(3):331–44CrossRefGoogle Scholar
  30. Maki PM, Freeman EW, Greendale GA, Henderson VW, Newhouse PA, Schmidt PJ, Scott NF, Shively CA, Soares CN (2010) Summary of the national institute on aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause 17:815–822PubMedCentralPubMedCrossRefGoogle Scholar
  31. Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD (2014) Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Drug Des Devel Ther 8:1685–93PubMedCentralPubMedCrossRefGoogle Scholar
  32. Marsh L, Biglan K, Gerstenhaber M, Williams JR (2009) Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov Disord 24:277–282PubMedCentralPubMedCrossRefGoogle Scholar
  33. Mathews M, Abner E, Caban-Holt A, Dennis BC, Kryscio R, Schmitt F (2013) Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Curr Alzheimer Res 10(7):776–83PubMedCentralPubMedCrossRefGoogle Scholar
  34. Ragland JD, Turetsky BI, Gur RC, Gunning-Dixon F, Turner T, Schroeder L, Chan R, Gur RE (2002) Working memory for complex figures: an fMRI comparison of letter and fractal n-back tasks. Neuropsychology 16:370–379PubMedCentralPubMedCrossRefGoogle Scholar
  35. Rapp SR, Espeland MA, Manson JE, Resnick SM, Bryan NR, Smoller S, Coker LH, Phillips LS, Stefanick ML, Sarto GE, Women’s Health Initiative Memory Study (2013) Educational attainment, MRI changes, and cognitive function in older postmenopausal women from the Women’s Health Initiative Memory Study. Int J Psychiatry Med 46:121–143PubMedCrossRefGoogle Scholar
  36. Ryan J, Scali J, Carriere I, Amieva H, Rouaud O, Berr C, Ritchie K, Ancelin ML (2014). Impact of a premature menopause on cognitive function in later life. BJOGGoogle Scholar
  37. Rypma B, Berger JS, D’Esposito M (2002) The influence of working-memory demand and subject performance on prefrontal cortical activity. J Cogn Neurosci 14:721–731PubMedCrossRefGoogle Scholar
  38. Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK (2008) Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord 11:445–458PubMedCrossRefGoogle Scholar
  39. Shanmugan S, Epperson CN (2014) Estrogen and the prefrontal cortex: towards a new understanding of estrogen’s effects on executive functions in the menopause transition. Hum Brain Mapp 35:847–865PubMedCentralPubMedCrossRefGoogle Scholar
  40. Sherwin BB (2005) Surgical menopause, estrogen, and cognitive function in women: what do the findings tell us? Ann N Y Acad Sci 1052:3–10PubMedCrossRefGoogle Scholar
  41. Stahl SM (2003) Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 64:110–111PubMedCrossRefGoogle Scholar
  42. Weber MT, Maki PM, McDermott MP (2014) Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol 142:90–98PubMedCrossRefGoogle Scholar
  43. Wegesin DJ, Stern Y (2007) Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 14:301–328PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • C. Neill Epperson
    • 1
    • 2
    • 3
  • Sheila Shanmugan
    • 1
    • 3
  • Deborah R. Kim
    • 1
    • 3
  • Sarah Mathews
    • 1
    • 3
  • Kathryn A. Czarkowski
    • 1
    • 3
  • Jeanette Bradley
    • 1
    • 3
  • Dina H. Appleby
    • 1
    • 3
  • Claudia Iannelli
    • 1
    • 3
  • Mary D. Sammel
    • 3
    • 4
  • Thomas E. Brown
    • 5
  1. 1.Department of PsychiatryPerelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Obstetrics and GynecologyPerelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA
  3. 3.Penn Center for Women’s Behavioral WellnessPerelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA
  4. 4.Department of Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphiaUSA
  5. 5.Department of PsychiatryYale University School of MedicineNew HavenUSA

Personalised recommendations